182 related articles for article (PubMed ID: 23041589)
21. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
[TBL] [Abstract][Full Text] [Related]
22. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
23. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.
Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N
J BUON; 2017; 22(2):487-494. PubMed ID: 28534374
[TBL] [Abstract][Full Text] [Related]
24. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
25. Impact of age on clinical risk scores in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
[TBL] [Abstract][Full Text] [Related]
27. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M
Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296
[TBL] [Abstract][Full Text] [Related]
28. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
29. Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model.
Andjelić B; Todorović-Balint M; Antić D; Bila J; Djurašinović V; Mihaljević B
Vojnosanit Pregl; 2015 Jan; 72(1):26-32. PubMed ID: 26043587
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
[TBL] [Abstract][Full Text] [Related]
31. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
32. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Batlevi CL; Sha F; Alperovich A; Ni A; Smith K; Ying Z; Soumerai JD; Caron PC; Falchi L; Hamilton A; Hamlin PA; Horwitz SM; Joffe E; Kumar A; Matasar MJ; Moskowitz AJ; Moskowitz CH; Noy A; Owens C; Palomba LM; Straus D; von Keudell G; Zelenetz AD; Seshan VE; Younes A
Blood Cancer J; 2020 Jul; 10(7):74. PubMed ID: 32678074
[TBL] [Abstract][Full Text] [Related]
33. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
Xue LG; Shen HR; Gao R; Du KX; Xing TY; Wang WT; Wang L; Li JY; Liang JH; Xu W
Ann Hematol; 2023 Apr; 102(4):851-862. PubMed ID: 36735075
[TBL] [Abstract][Full Text] [Related]
34. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
35. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
Madsen C; Clausen MR; Plesner TL; Pasanen A; Kuismanen T; Bentzen HH; Jørgensen JM; Sillesen IB; Himmelstrup BM; Rønnov-Jessen D; Jensen KR; Pettinger AM; Ludvigsen M; Leppä S; d'Amore FA
Blood Adv; 2018 Jul; 2(13):1562-1571. PubMed ID: 29976619
[TBL] [Abstract][Full Text] [Related]
36. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
37. Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
Helbig G; Krawczyk-Kulis M; Kopinska A; Liwoch R; Kyrcz-Krzemien S
Med Oncol; 2014 Dec; 31(12):310. PubMed ID: 25373321
[TBL] [Abstract][Full Text] [Related]
38. Follicular lymphoma in the United States: first report of the national LymphoCare study.
Friedberg JW; Taylor MD; Cerhan JR; Flowers CR; Dillon H; Farber CM; Rogers ES; Hainsworth JD; Wong EK; Vose JM; Zelenetz AD; Link BK
J Clin Oncol; 2009 Mar; 27(8):1202-8. PubMed ID: 19204203
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).
Wagner-Johnston ND; Link BK; Byrtek M; Dawson KL; Hainsworth J; Flowers CR; Friedberg JW; Bartlett NL
Blood; 2015 Aug; 126(7):851-7. PubMed ID: 26105149
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?
Prochazka V; Papajik T; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):99-108. PubMed ID: 21804618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
